WithdrawnPhase 2

Study of the Safety of Two Doses of Investigational Study Drug EVP-6124 in Subjects With Alzheimer's Disease Currently Receiving Memantine

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 24-Week, Phase 2 Study of Two Doses of EVP-6124 Hydrochloride or Placebo in Subjects With Mild to Moderate Alzheimer's Disease Currently Receiving Memantine Medication With or Without Additional Acetylcholinesterase Inhibitor Co-Medication

Lead sponsor

FORUM Pharmaceuticals Inc

Asset

EVP-6124

Listed sites

Recruiting sites

Enrollment

actual

Study population

Alzheimer’s disease

Key I/E criteria

•Alzheimer's disease•MMSE 12-26•Study partner/caregiver required•AD symptomatic therapy: stable ≥3 months

Primary endpoint

•Safety/Tolerability of EVP-6124 with concurrent memantine

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

Org study IDEVP-6124-027

NCT IDNCT02246075

Timeline

Milestones

Study first posted2014-09-22estimated

Study start2015-07 (month precision)

Last update posted2015-10-15estimated

Primary completion2016-10estimated (month precision)

Assets

Drug assets

EVP-6124

Study populations

Who this study enrolls

Alzheimer’s disease

Eligibility

Who can enroll

Minimum age55 Years

Maximum age85 Years

SexAll

Healthy volunteersNot accepted

Inclusion criteria

•Ages ≥55 and ≤85 years

•Informed consent form (ICF) signed by the subject or legally acceptable representative before any study-specific procedures for the subject are performed and an ICF signed by the support person/caregiver before any study-specific procedures for the support person/caregiver are performed

•Clinical diagnosis of dementia due to possible or probable AD consistent with criteria established by a workgroup of the National Institute on Aging and the Alzheimer's Disease Association

•Magnetic resonance imaging (MRI) or computed tomography (CT) scan performed within 12 months before screening, with findings consistent with the diagnosis of dementia due to AD without any other clinically significant comorbid pathologies. If an MRI or CT scan is unavailable or occurred greater than 12 months before screening, this assessment should be completed and the findings confirmed before the subject enters the run-in period (Day -14) (copy of the report will be available at the study site)

•Mini-Mental State Examination (MMSE) score ≥12 and ≤26 at screening

•Modified Hachinski Ischemic Scale (mHIS) score ≤4 at screening

•Fertile, sexually active subjects (men and women) must use an effective method of contraception during the study. Female subjects and the female partner of male subjects must be surgically sterile (hysterectomy or bilateral tubal ligation), postmenopausal for at least 1-year, or willing to practice adequate methods of contraception if of childbearing potential (defined as consistent use of combined effective methods of contraception [including at least 1 barrier method])

•Reliable and capable support person/caregiver, who if not living in the same household, interacts with the subject regularly and will help facilitate clinic visits of the study subject

•Subject living at home, senior residential setting, or an institutional setting without the need for continuous (ie, 24-hour) nursing care

•General health status acceptable for participation in a 24-week study

•Fluency (oral and written) in the language in which the standardized tests will be administered

•Receiving a stable dose of memantine for at least 3 months (90 days) before screening and with continuous dosing for at least 3 months. Additional co-medication with an AChEI (donepezil in any dose form other than 23 mg once daily (QD), rivastigmine or galantamine) is allowed if stable for at least 3 months (90 days) before screening with total continuous exposure for at least 3 months

Exclusion criteria

•Exposure to an experimental drug, experimental biologic or experimental medical device within 2 months (60 days) before screening

•Prior participation in an amyloid vaccination clinical study at any time in the past or completion of a passive amyloid vaccination study within 6 months before screening

•Inability to swallow a tablet

•In the judgment of the investigator, inability of the subject to complete a 24-week study

•Residence in a skilled nursing facility

•Inability to be ≥75% compliant with single-blind study drug

•Clinically significant (in the judgment of the investigator) abnormal serum electrolytes (sodium, potassium, magnesium) after repeat testing

•Clinically significant untreated hypothyroidism (if treated, thyroid-stimulating hormone level and thyroid supplementation dose must be stable for at least 6 months before screening)

•Insufficiently controlled diabetes mellitus (in the judgment of the investigator) or requiring insulin

•Renal insufficiency (serum creatinine >2.0 mg/dL)

•Malignant tumor within 3 years before screening (except squamous and basal cell carcinoma or cervical carcinoma in situ or localized prostate cancer)

•History of ischemic colitis or ischemic enterocolitis

•Unstable medical condition that is clinically significant in the judgment of the investigator

•Female subjects who are pregnant, nursing, or planning to become pregnant during the study

•Alanine transaminase (ALT) or aspartate transaminase (AST) >2.5 times the upper limit of normal

•History of myocardial infarction or unstable angina within 6 months before screening

•History of more than 1 myocardial infarction within 5 years before screening

•Clinically significant (in the judgment of the investigator) cardiac arrhythmia (including atrial fibrillation), cardiomyopathy, or cardiac conduction defect (subjects with a pacemaker are acceptable)

•Symptomatic hypotension, or uncontrolled hypertension (in the judgment of the investigator)

•Clinically significant abnormality on screening electrocardiogram (ECG), including but not necessarily limited to a confirmed QTc value ≥450 msec for males or ≥470 msec for females. In subjects with a QRS value >120msec, those with a QTc value <500 msec may be eligible following discussion with the Medical Monitor.

•Stroke within 18 months before screening, or history of a stroke concomitant with onset of dementia

•History of brain tumor, subdural hematoma, or other clinically significant (in the judgment of the investigator) space-occupying lesion on CT or MRI

•Head trauma with clinically significant (in the judgment of the investigator) loss of consciousness within 12 months before screening or concurrent with the onset of dementia

•Onset of dementia secondary (in the judgment of the investigator) to cardiac arrest, surgery with general anesthesia, or resuscitation

•Specific degenerative CNS disease diagnosis other than AD (eg, Huntington's disease, Creutzfeld-Jacob disease, Down's syndrome, Fronto-Temporal Dementia, Parkinson's disease)

•Wernicke's encephalopathy

•Active acute or chronic CNS infection

•Donepezil 23 mg QD currently or within 3 months prior to randomization

•Discontinued AChEI <30 days prior to randomization

•Antipsychotics; low doses (in the judgment of the investigator, except clozapine) are allowed only if given for sleep disturbances, agitation and/or aggression, and only if the subject has received a stable dose for at least 3 months before randomization

•Tricyclic antidepressants and monoamine oxidase inhibitors; all other antidepressants are allowed only if the subject has received a stable dose for at least 3 months before randomization

•Anxiolytics or sedative-hypnotics, including barbiturates (unless given in low doses for benign tremor); low doses of benzodiazepines and zolpidem (in the judgment of the investigator) are allowed only if given for insomnia/sleep disturbance, and only if the subject has received a stable dose for at least 3 months before randomization

•Peripherally acting drugs with effects on cholinergic transmission

•Immunosuppressants, including systemic corticosteroids, if taken in clinically immunosuppressive doses in the judgment of the investigator (Note: steroid use for allergy or other inflammation is permitted)

•Antiepileptic medications if taken for control of seizures

•Chronic intake of opioid-containing analgesics

•Sedating H1 antihistamines

•Nicotine therapy (all dosage forms including a patch), varenicline (Chantix), or similar therapeutic agent within 30 days before screening

•Clinically significant urine drug screen (UDS) or serum alcohol test result in the judgment of the investigator (including medical marijuana)

Endpoints (2)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Global cognition

Safety / tolerability / PK

Global cognition

1 endpoint

Secondary/protocol endpoint

Change from Baseline in the Mini-Mental State Examination (MMSE)

Time frame:Baseline to Day 168

Mini-Mental State Examination (MMSE)

change from baseline, improvement

Safety / tolerability / PK

1 endpoint

Primary/protocol endpoint

Safety/Tolerability of EVP-6124 with concurrent memantine

Time frame:Baseline to Day 168

threshold achievement, event

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 21, 2026

Endpoint classificationDelfa ADRD endpoint taxonomy

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 21, 2026 snapshot.